Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.68 USD | -0.43% | -2.45% | +67.74% |
May. 01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
Financials (USD)
Sales 2024 * | 2.03M | Sales 2025 * | - | Capitalization | 25.03M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | - | EV / Sales 2024 * | 12.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.14
x | P/E ratio 2025 * |
-
| Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.09% |
1 day | -0.43% | ||
1 week | -2.45% | ||
Current month | +1.30% | ||
1 month | +1.52% | ||
3 months | +18.78% | ||
6 months | +81.40% | ||
Current year | +67.74% |
Managers | Title | Age | Since |
---|---|---|---|
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
Anthony DelConte
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Krista Fogarty
AUD | Comptroller/Controller/Auditor | 56 | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dana Ono
BRD | Director/Board Member | 71 | 14-01-05 |
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
John W. Higuchi
BRD | Director/Board Member | 56 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 4.68 | -0.43% | 68,664 |
24-05-02 | 4.7 | -0.21% | 25,742 |
24-05-01 | 4.71 | +1.95% | 9,055 |
24-04-30 | 4.62 | -2.33% | 28,681 |
24-04-29 | 4.73 | -1.41% | 28,711 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.74% | 25.03M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- LPCN Stock